spevatamig + fluorouracil + leucovorin + oxaliplatin

This drug is a **combination therapeutic regimen** that consists of **spevatamig**, **fluorouracil**, **leucovorin**, and **oxaliplatin**. While fluorouracil, leucovorin, and oxaliplatin are a well-established combination (commonly known as FOLFOX), the inclusion of spevatamig is novel; there is no substantive or peer-reviewed clinical data available for "spevatamig," suggesting it may be an investigational or novel agent not yet approved or documented in major medical literature. Fluorouracil (5-FU) is a pyrimidine analog and antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis[1][2][3][4][6]. Leucovorin (folinic acid) is used to enhance the efficacy of fluorouracil by stabilizing the binding of 5-FU to thymidylate synthase[1][2][3][4][6]. Oxaliplatin is a platinum-based chemotherapeutic that forms DNA cross-links, inhibiting replication and transcription[1][2][3][4][6]. The combined regimen is indicated primarily for the treatment of metastatic colorectal cancer and as adjuvant therapy for stage II and III colon cancer, and is administered by intravenous infusion[1][2][3][4][6].